Abstract | BACKGROUND: METHODS: Patients presenting with rapidly progressive bilateral hearing loss who had a documented history of hydrocodone use were selected for the study. The presentation, audiologic findings, associated comorbidities, and treatment outcomes were reviewed. RESULTS: All patients displayed rapidly progressive sensorineural hearing loss without vestibular symptoms. Hearing loss was asymmetric in 3 patients at initial presentation, but progressed to profound loss, usually within months. Steroid treatment has no effect on the progression of the hearing loss. The admitted quantity of hydrocodone consumed ranged from 10 to 300 mg per day. Hepatitis C was the most common comorbidity, present in 60% of the patients. All patients underwent cochlear implantation with satisfactory results. CONCLUSIONS:
|
Authors | Tang Ho, Jeffrey T Vrabec, Allen W Burton |
Journal | Pain physician
(Pain Physician)
Vol. 10
Issue 3
Pg. 467-72
(May 2007)
ISSN: 1533-3159 [Print] United States |
PMID | 17525781
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Analgesics, Opioid
- Anti-Inflammatory Agents, Non-Steroidal
- Neurotoxins
- Acetaminophen
- Hydrocodone
- Cytochrome P-450 CYP2D6
|
Topics |
- Acetaminophen
(adverse effects)
- Adult
- Analgesics, Opioid
(adverse effects, pharmacokinetics)
- Anti-Inflammatory Agents, Non-Steroidal
(adverse effects)
- Cochlea
(drug effects, physiopathology)
- Cochlear Implants
- Comorbidity
- Cytochrome P-450 CYP2D6
(genetics)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Hearing Loss, Sensorineural
(chemically induced, physiopathology)
- Hepatitis C
(epidemiology)
- Humans
- Hydrocodone
(adverse effects, pharmacokinetics)
- Inactivation, Metabolic
(genetics)
- Male
- Middle Aged
- Neurotoxins
(adverse effects, pharmacokinetics)
|